Effect of Tea Polyphenol Compounds on Anticancer Drugs in Terms of Anti-Tumor Activity, Toxicology, and Pharmacokinetics

Overview

Journal Nutrients

Date 2016 Dec 17

PMID 27983622

Citations 35

Authors

Jianhua Cao

Jie Han

Hao Xiao

Jinping Qiao

Mei Han

Affiliations

Soon will be listed here.

Abstract

Multidrug resistance and various adverse side effects have long been major problems in cancer chemotherapy. Recently, chemotherapy has gradually transitioned from mono-substance therapy to multidrug therapy. As a result, the drug cocktail strategy has gained more recognition and wider use. It is believed that properly-formulated drug combinations have greater therapeutic efficacy than single drugs. Tea is a popular beverage consumed by cancer patients and the general public for its perceived health benefits. The major bioactive molecules in green tea are catechins, a class of flavanols. The combination of green tea extract or green tea catechins and anticancer compounds has been paid more attention in cancer treatment. Previous studies demonstrated that the combination of chemotherapeutic drugs and green tea extract or tea polyphenols could synergistically enhance treatment efficacy and reduce the adverse side effects of anticancer drugs in cancer patients. In this review, we summarize the experimental evidence regarding the effects of green tea-derived polyphenols in conjunction with chemotherapeutic drugs on anti-tumor activity, toxicology, and pharmacokinetics. We believe that the combination of multidrug cancer treatment with green tea catechins may improve treatment efficacy and diminish negative side effects.

Citing Articles

Green Tea: Current Knowledge and Issues.

Radeva-Ilieva M, Stoeva S, Hvarchanova N, Georgiev K Foods. 2025; 14(5).

PMID: 40077449 PMC: 11899301. DOI: 10.3390/foods14050745.

Natural Copper Ion Scavenger: Investigation of the Hepatoprotective Effects of Green Tea Extract in Toxic-Milk Mice with Wilson's Disease Model.

Yang D, Xuan S, Zhang W, Wu H, Jiang Y, Zhou A Foods. 2025; 14(4).

PMID: 40002122 PMC: 11854454. DOI: 10.3390/foods14040679.

Appearance of green tea compounds in plasma following acute green tea consumption is modulated by the gut microbiome in mice.

Sterrett J, Quinn K, Doenges K, Nusbacher N, Levens C, Armstrong M Microbiol Spectr. 2025; 13(2):e0179924.

PMID: 39791884 PMC: 11792465. DOI: 10.1128/spectrum.01799-24.

Appearance of green tea compounds in plasma following acute green tea consumption is modulated by the gut microbiome in mice.

Sterrett J, Quinn K, Doenges K, Nusbacher N, Levens C, Armstrong M bioRxiv. 2024; .

PMID: 39605610 PMC: 11601224. DOI: 10.1101/2024.07.11.603097.

Prospecting Pharmacologically Active Biocompounds from the Amazon Rainforest: In Vitro Approaches, Mechanisms of Action Based on Chemical Structure, and Perspectives on Human Therapeutic Use.

de Almada-Vilhena A, Dos Santos O, Machado M, Nagamachi C, Pieczarka J Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598361 PMC: 11597570. DOI: 10.3390/ph17111449.

References

Glynn S, Gaffney K, Sainz M, Louie S, Petasis N . Molecular characterization of the boron adducts of the proteasome inhibitor bortezomib with epigallocatechin-3-gallate and related polyphenols. Org Biomol Chem. 2015; 13(13):3887-99. PMC: 4366333. DOI: 10.1039/c4ob02512a. View

Tang S, Singh C, Nall D, Meeker D, Shankar S, Srivastava R . The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal. 2010; 5:14. PMC: 2933702. DOI: 10.1186/1750-2187-5-14. View

Tsuchiya H, Mori Y, Ueda Y, Okada G, Tomita K . Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma. Anticancer Res. 2000; 20(1A):235-42. View

Adhami V, Malik A, Zaman N, Sarfaraz S, Siddiqui I, Syed D . Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res. 2007; 13(5):1611-9. DOI: 10.1158/1078-0432.CCR-06-2269. View

Sriram N, Kalayarasan S, Sudhandiran G . Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis. Chem Biol Interact. 2009; 180(2):271-80. DOI: 10.1016/j.cbi.2009.02.017. View

Scandlyn M, Stuart E, Somers-Edgar T, Menzies A, Rosengren R . A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer. 2008; 99(7):1056-63. PMC: 2567064. DOI: 10.1038/sj.bjc.6604634. View

Qiao J, Gu C, Shang W, Du J, Yin W, Zhu M . Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro. Food Chem Toxicol. 2011; 49(6):1410-5. DOI: 10.1016/j.fct.2011.03.033. View

Golden E, Lam P, Kardosh A, Gaffney K, Cadenas E, Louie S . Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 2009; 113(23):5927-37. DOI: 10.1182/blood-2008-07-171389. View

Amin A, Wang D, Zhang H, Peng S, Shin H, Brandes J . Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem. 2010; 285(45):34557-65. PMC: 2966071. DOI: 10.1074/jbc.M110.141135. View

10.

Bannerman B, Xu L, Jones M, Tsu C, Yu J, Hales P . Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol. 2011; 68(5):1145-54. PMC: 3215871. DOI: 10.1007/s00280-011-1591-2. View

11.

Kim M, Chung J . Synergistic cell death by EGCG and ibuprofen in DU-145 prostate cancer cell line. Anticancer Res. 2008; 27(6B):3947-56. View

12.

Henning S, Wang P, Said J, Huang M, Grogan T, Elashoff D . Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate. 2014; 75(5):550-9. PMC: 4334734. DOI: 10.1002/pros.22943. View

13.

Farabegoli F, Papi A, Orlandi M . (-)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci Rep. 2010; 31(2):99-108. DOI: 10.1042/BSR20090143. View

14.

Stearns M, Wang M . Synergistic Effects of the Green Tea Extract Epigallocatechin-3-gallate and Taxane in Eradication of Malignant Human Prostate Tumors. Transl Oncol. 2011; 4(3):147-56. PMC: 3104695. DOI: 10.1593/tlo.10286. View

15.

Chan M, Soprano K, Weinstein K, Fong D . Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol. 2006; 207(2):389-96. DOI: 10.1002/jcp.20569. View

16.

Fujiki H, Imai K, Nakachi K, Shimizu M, Moriwaki H, Suganuma M . Challenging the effectiveness of green tea in primary and tertiary cancer prevention. J Cancer Res Clin Oncol. 2012; 138(8):1259-70. DOI: 10.1007/s00432-012-1250-y. View

17.

Yang X, Wang X, Cao L, Jiang X, Peng H, Lin S . Green tea polyphenol epigallocatechin-3-gallate enhances 5-fluorouracil-induced cell growth inhibition of hepatocellular carcinoma cells. Hepatol Res. 2012; 42(5):494-501. DOI: 10.1111/j.1872-034X.2011.00947.x. View

18.

Chari N, Pinaire N, Thorpe L, Medeiros L, Routbort M, McDonnell T . The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis. 2009; 14(4):336-47. DOI: 10.1007/s10495-009-0327-9. View

19.

Ahmad K, Harris N, Johnson A, Lindvall H, Wang G, Ahmed K . Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells. Mol Cancer Ther. 2007; 6(3):1006-12. DOI: 10.1158/1535-7163.MCT-06-0491. View

20.

Suganuma M, Okabe S, Kai Y, Sueoka N, Sueoka E, Fujiki H . Synergistic effects of (--)-epigallocatechin gallate with (--)-epicatechin, sulindac, or tamoxifen on cancer-preventive activity in the human lung cancer cell line PC-9. Cancer Res. 1999; 59(1):44-7. View